NCT03798626 : Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Stomach and upper gastrointestinal tract,Urinary systemColorectum,Gastro-oesophageal junction ,Kidney,Oesophagus,Stomach

Trial Overview Read MoreRead more

This phase I trial is testing a new immunotherapy drug (Gevokizumab) in combination with other standard therapies for the treatment of colorectal cancers, gastroesophageal cancers and renal cell carcinomas that have spread to other parts of the body.
 

This trial is treating patients with Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma

Commercial Sponsor

Novartis Pharmaceuticals

Summary

This is a non-randomised trial, in which eligible participants will be assigned to a tumour-defined treating arm. Patients with first line colorectal cancer will receive intravenous (IV) Gevokizumab, modified FOLFOX6 chemotherapy and bevacizumab. Patients with second line colorectal cancer will receive IV Gevokizumab, FOLFIRI and bevacizumab. Treatment for second line metastatic gastroesophageal cancer (mGEC) will include Gevokizumab, paclitaxel and ramucirumab. Patients with second or third line renal cell carcinoma will receive IV Gevokizumab in combination with oral cabozantinib.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next